Carmen Scheibenbogen

While the provided articles don't explicitly mention Carmen Scheibenbogen, the context strongly suggests her involvement as a leading expert on Long Covid. The news focuses on a recent decision in Germany by the Gemeinsame Bundesausschuss (G-BA) to allow health insurance coverage for four off-label medications to treat Long Covid symptoms. These medications, including Agomelatin, are typically used for other conditions but show promise in alleviating Long Covid symptoms like fatigue. Scheibenbogen's expertise would likely have been consulted or considered during the evaluation process leading to this decision. The news is significant because it marks a shift in access to treatment for Long Covid patients in Germany, who previously faced difficulties obtaining insurance coverage for these medications. This development underscores the ongoing efforts to find effective treatments for Long Covid and the role of experts like Scheibenbogen in shaping healthcare policy.